WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced it has appointed Joshua C. Brown, MD, PhD, as chief medical innovation officer to support the company’s development of treatments for depression and post-traumatic stress disorder.
Brown is a psychiatrist, neurologist, and neuroscientist who studies the mechanisms of transcranial magnetic stimulation, a therapy used to treat certain neurological and psychiatric conditions.
He currently serves as medical director of the Transcranial Magnetic Stimulation Service at McLean Hospital and directs the Brain Stimulation Mechanisms Laboratory.
Brown also holds an appointment as assistant professor of psychiatry at Harvard Medical School.
In addition, he serves as president of the Clinical TMS Society and editor-in-chief of the Transcranial Magnetic Stimulation journal.
NRx said Brown will help advance research involving transcranial magnetic stimulation combined with neuroplastic medications.
His research has focused on using the therapy to treat depression and PTSD, including work funded by the National Institute of Mental Health and the Defense Advanced Research Projects Agency.
The company said Brown will collaborate with Dennis McBride, PhD, NRx’s chief strategy officer, on efforts related to treatments for military personnel, veterans, and first responders.
NRx has filed an investigational new drug application with the U.S. Food and Drug Administration to test a treatment approach combining ketamine, transcranial magnetic stimulation, hyperbaric oxygen, and the company’s drug candidate NRX-101.
Chief Executive Officer Jonathan Javitt said the appointment supports the company’s research programs.
“We are excited to have Dr. Brown bring his scientific leadership and clinical expertise to our drug development program and our focus on reversing PTSD and depression in military personnel, veterans, and first responders,” Javitt said.
Brown said his role will focus on integrating neuroscience research into treatments for psychiatric disorders.
“My focus will be to accelerate the integration of neuroscience into scalable, evidence-based treatments that can transform outcomes for patients suffering from serious brain disorders,” Brown said.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.